3 results match your criteria: "2nd Affiliated Hospital of Tianjin Medical University[Affiliation]"

Longer duration of catheter patency, but similar infection rates with internal jugular vein versus iliac vein tunneled cuffed hemodialysis catheters: a single-center retrospective analysis.

Int Urol Nephrol

October 2015

Department of Kidney Disease and Blood Purification Center, Institute of Urology and Key Laboratory of Tianjin, 2nd Affiliated Hospital of Tianjin Medical University, 23rd, Pingjiang Road, Hexi District, Tianjin, 300211, People's Republic of China.

Background: Although tunneled cuffed catheters (TCCs) are widely used in hemodialysis, little is known about their complications in elderly patients with hemodialysis. Furthermore, there is no report about which vessel access, either jugular or iliac vein, is superior for elderly patients requiring TCCs.

Methods: In the present study, we reviewed the clinical parameters of 127 patients aged over 65 years with 207 new TCC placements and measured the incidence of catheter patency, infection, dysfunction, and survival of TCCs.

View Article and Find Full Text PDF

Testicular orphan nuclear receptor 4 is associated with the radio-sensitivity of prostate cancer.

Prostate

October 2015

George Whipple Lab for Cancer Research, Department of Pathology, Urology and Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York.

Background: It is well known that a significant number of prostate cancers (PCa) showed different extents of radio-resistance and the tumor may recur after treatment. Recent studies demonstrated that Testicular orphan nuclear receptor 4 (TR4) could play a critical role in anti-oxidative stress responses and might modulate the DNA damage repair. The objective of this study is to investigate the role of TR4 in the radiotherapy for PCa.

View Article and Find Full Text PDF

The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer.

Cancer Gene Ther

October 2014

1] Department of Urology and Chawnshang Chang Liver Cancer Center, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China [2] George Whipple Lab for Cancer Research, Departments of Pathology, Urology and Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA.

Docetaxel-based therapy is one of the first-line options for castration-resistant prostate cancer (CRPC). However, a large proportion of CRPC patients show different extents of docetaxel resistance. The current study aims to investigate the role of testicular nuclear receptor 4 (TR4) in docetaxel resistance in CRPC.

View Article and Find Full Text PDF